{
    "hands_on_practices": [
        {
            "introduction": "Febrile neutropenia stands as one of the most common and time-sensitive oncologic emergencies. The ability to rapidly assess a patient's risk for serious complications is crucial for determining the appropriate site of care. This practice will sharpen two fundamental skills: the calculation of the Absolute Neutrophil Count (ANC) from a standard complete blood count with differential, and the application of a validated risk-stratification tool, such as the Multinational Association for Supportive Care in Cancer (MASCC) score, to guide management decisions. ",
            "id": "4854766",
            "problem": "A patient-specific scenario is provided to assess febrile neutropenia risk and management in an immunocompromised host. A $52$-year-old woman with stage $\\text{IIIB}$ triple-negative breast cancer on day $10$ after cycle $2$ of dose-dense anthracycline-based chemotherapy presents after developing a fever at home. She recorded a maximal oral temperature of $38.4^{\\circ}\\text{C}$ at home and arrives to the emergency department within $4$ hours. On arrival, vital signs are: temperature $38.3^{\\circ}\\text{C}$, heart rate $98 \\ \\text{beats/min}$, blood pressure $112/70 \\ \\text{mmHg}$, respiratory rate $16 \\ \\text{breaths/min}$, and oxygen saturation $98 \\%$ on room air. She reports mild fatigue and mild grade $1$ oral mucositis without odynophagia or dysphagia, no cough or dyspnea, no abdominal pain, no diarrhea, and no dysuria. Examination shows a well-appearing patient with moist mucous membranes, no orthostasis, no focal lung findings, no indwelling central venous catheter, and no signs of dehydration. There is no history of chronic obstructive pulmonary disease, no known prior invasive fungal infection, and she took no recent antibiotics. She was an outpatient at fever onset. Laboratory testing shows: white blood cell count $0.9 \\times 10^{9} \\text{ cells/L}$ with differential: segmented neutrophils $12 \\%$, band forms $6 \\%$, lymphocytes $65 \\%$, monocytes $10 \\%$, eosinophils $2 \\%$, basophils $1 \\%$, and metamyelocytes $4 \\%$; serum creatinine $0.8 \\ \\text{mg/dL}$; serum lactate $1.3 \\ \\text{mmol/L}$. Eastern Cooperative Oncology Group (ECOG) performance status is $1$.\n\nUsing foundational definitions and validated risk indices in febrile neutropenia for immunocompromised hosts in internal medicine, do all of the following:\n\n- Compute the absolute neutrophil count (ANC) from the provided white blood cell count and differential, expressed both in $10^{9}/\\text{L}$ and in $\\text{cells}/\\mu\\text{L}$.\n- Classify the patient’s febrile neutropenia risk tier and justify whether outpatient or inpatient management is appropriate by applying validated thresholds from either the Multinational Association for Supportive Care in Cancer (MASCC) risk index or the Clinical Index of Stable Febrile Neutropenia (CISNE), and explicitly explain why the chosen tool is appropriate for this scenario.\n- For the purpose of a single numerical final answer, report the computed MASCC risk index score. No rounding is required. Express the final answer as the MASCC score only (no units).",
            "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- **Patient Demographics:** $52$-year-old woman.\n- **Oncologic History:** Stage $\\text{IIIB}$ triple-negative breast cancer.\n- **Treatment Status:** Day $10$ after cycle $2$ of dose-dense anthracycline-based chemotherapy.\n- **Presentation:** Onset of fever as an outpatient, arrival to emergency department within $4$ hours.\n- **Vital Signs:** Maximal oral temperature at home $38.4^{\\circ}\\text{C}$; arrival temperature $38.3^{\\circ}\\text{C}$, heart rate $98 \\ \\text{beats/min}$, blood pressure $112/70 \\ \\text{mmHg}$, respiratory rate $16 \\ \\text{breaths/min}$, oxygen saturation $98 \\%$ on room air.\n- **Symptoms:** Mild fatigue, mild grade $1$ oral mucositis. No odynophagia, dysphagia, cough, dyspnea, abdominal pain, diarrhea, or dysuria.\n- **Physical Examination:** Well-appearing, moist mucous membranes, no orthostasis, no focal lung findings, no indwelling central venous catheter, no signs of dehydration.\n- **Comorbidities/History:** No chronic obstructive pulmonary disease (COPD), no known prior invasive fungal infection, no recent antibiotic use.\n- **Performance Status:** Eastern Cooperative Oncology Group (ECOG) performance status of $1$.\n- **Laboratory Data:**\n    - White blood cell (WBC) count: $0.9 \\times 10^{9} \\text{ cells/L}$.\n    - Differential: segmented neutrophils $12 \\%$, band forms $6 \\%$, lymphocytes $65 \\%$, monocytes $10 \\%$, eosinophils $2 \\%$, basophils $1 \\%$, metamyelocytes $4 \\%$.\n    - Serum creatinine: $0.8 \\ \\text{mg/dL}$.\n    - Serum lactate: $1.3 \\ \\text{mmol/L}$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the validation criteria.\n- **Scientifically Grounded:** The scenario describes a classic and medically realistic presentation of febrile neutropenia in a patient with a solid tumor receiving myelosuppressive chemotherapy. All clinical and laboratory parameters are plausible. The requested tasks—calculating the absolute neutrophil count (ANC) and applying validated risk indices (MASCC, CISNE)—are standard procedures in internal medicine and oncology. The problem is based on established medical definitions and evidence-based guidelines.\n- **Well-Posed:** The problem is well-defined and self-contained. It provides all necessary data to perform the requested calculations and risk stratification. The objectives are clear: compute the ANC, assess risk to determine management location, and report the MASCC score. A unique and meaningful solution exists.\n- **Objective:** The language is clinical, precise, and free of subjective or biased statements.\n- **Conclusion:** The problem statement is free of scientific flaws, inconsistencies, or ambiguities. It is a valid, well-posed problem grounded in established medical practice.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution\n\nThe solution proceeds by addressing the three components of the problem: computing the absolute neutrophil count (ANC), performing risk stratification to guide management, and reporting the final numerical score.\n\n**Part 1: Absolute Neutrophil Count (ANC) Calculation**\nFebrile neutropenia is defined by the presence of fever (typically a single oral temperature $\\ge 38.3^{\\circ}\\text{C}$ or a temperature $\\ge 38.0^{\\circ}\\text{C}$ sustained over a $1$-hour period) and neutropenia. The patient's recorded temperature of $38.4^{\\circ}\\text{C}$ satisfies the fever criterion. Neutropenia is defined by the ANC.\n\nThe ANC is calculated by multiplying the total white blood cell (WBC) count by the sum of the percentages of mature (segmented) neutrophils and immature (band) neutrophils.\n\nThe formula is:\n$$\n\\text{ANC} = (\\text{WBC count}) \\times (\\% \\text{Segmented Neutrophils} + \\% \\text{Band Forms})\n$$\n\nUsing the provided laboratory values:\n- WBC count = $0.9 \\times 10^{9} \\text{ cells/L}$\n- $\\%$ Segmented Neutrophils = $12 \\% = 0.12$\n- $\\%$ Band Forms = $6 \\% = 0.06$\n\nFirst, we compute the ANC in units of $10^{9} \\text{ cells/L}$:\n$$\n\\text{ANC} = (0.9 \\times 10^{9} \\text{ cells/L}) \\times (0.12 + 0.06)\n$$\n$$\n\\text{ANC} = (0.9 \\times 10^{9} \\text{ cells/L}) \\times 0.18\n$$\n$$\n\\text{ANC} = 0.162 \\times 10^{9} \\text{ cells/L}\n$$\n\nNext, we convert this value to units of $\\text{cells}/\\mu\\text{L}$ (also commonly reported as $\\text{cells}/\\text{mm}^3$). The conversion factor is $1 \\times 10^{9} \\text{ cells/L} = 1000 \\text{ cells}/\\mu\\text{L}$.\n$$\n\\text{ANC} = 0.162 \\times 1000 \\text{ cells}/\\mu\\text{L} = 162 \\text{ cells}/\\mu\\text{L}\n$$\n\nThe calculated ANC of $162 \\text{ cells}/\\mu\\text{L}$ is less than the threshold of $500 \\text{ cells}/\\mu\\text{L}$, confirming the diagnosis of febrile neutropenia. Specifically, this qualifies as severe neutropenia ($\\text{ANC}  500 \\text{ cells}/\\mu\\text{L}$).\n\n**Part 2: Risk Stratification and Management Recommendation**\nThe problem requires using either the MASCC or CISNE score to risk-stratify the patient and justify the choice. The final answer requires the MASCC score, so we will use the MASCC index for the primary analysis.\n\nThe Multinational Association for Supportive Care in Cancer (MASCC) risk index is a widely validated tool used to identify patients with febrile neutropenia who are at low risk for serious complications and are thus potential candidates for outpatient management. It is appropriate for this patient, who has a solid tumor and presents with febrile neutropenia. A score of $\\ge 21$ indicates low risk, while a score $ 21$ indicates high risk.\n\nThe MASCC score is calculated by summing points for various clinical features:\n- **Burden of illness at onset of fever:** The patient reports \"mild fatigue and mild grade $1$ oral mucositis\" with no other significant symptoms. This corresponds to **no or mild symptoms**, which awards $5$ points.\n- **Absence of hypotension:** The patient's blood pressure is $112/70 \\ \\text{mmHg}$, with systolic pressure ($112 \\ \\text{mmHg}$) well above the threshold of $90 \\ \\text{mmHg}$. This awards $5$ points.\n- **Absence of Chronic Obstructive Pulmonary Disease (COPD):** The history explicitly states \"no history of chronic obstructive pulmonary disease.\" This awards $4$ points.\n- **Solid tumor or hematologic malignancy with no previous fungal infection:** The patient has a solid tumor (breast cancer) and \"no known prior invasive fungal infection.\" This awards $4$ points.\n- **Absence of dehydration requiring parenteral fluids:** The examination shows \"moist mucous membranes\" and \"no signs of dehydration.\" This awards $3$ points.\n- **Outpatient status at onset of fever:** The history states \"She was an outpatient at fever onset.\" This awards $3$ points.\n- **Age:** The patient is $52$ years old, which is less than $60$ years. This awards $2$ points.\n\nThe total MASCC score is the sum of these points:\n$$\n\\text{MASCC Score} = 5 + 5 + 4 + 4 + 3 + 3 + 2 = 26\n$$\nA score of $26$ is $\\ge 21$, which classifies the patient as **low-risk** for complications. Based on this low-risk categorization, and in the context of her overall clinical stability (well-appearing, stable vital signs, no significant comorbidities), she is a suitable candidate for outpatient management with oral antibiotics, provided appropriate outpatient infrastructure for monitoring and follow-up is available. The Clinical Index of Stable Febrile Neutropenia (CISNE) would also classify this patient as low-risk (score of $1$, based on a monocyte count $200/\\mu\\text{L}$), corroborating the MASCC assessment.\n\n**Part 3: Final Numerical Answer**\nThe problem explicitly requests the computed MASCC risk index score as the final answer. Based on the calculation above, the score is $26$.",
            "answer": "$$\\boxed{26}$$"
        },
        {
            "introduction": "Beyond managing acute infections, preventing them is a cornerstone of caring for the immunocompromised host. Effective prophylaxis against opportunistic pathogens like *Pneumocystis jirovecii* requires more than simply identifying an at-risk patient; it demands precise pharmacologic management. This exercise provides a practical, multi-step challenge in tailoring a prophylactic regimen, requiring you to integrate patient-specific factors like body composition and renal function to arrive at a safe and effective dose. ",
            "id": "4854700",
            "problem": "A $70$-year-old man with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has received a single infusion of rituximab and is on oral prednisone at $40\\,\\mathrm{mg/day}$ for $6$ consecutive weeks along with oral cyclophosphamide induction. His absolute lymphocyte count is $250\\,\\mathrm{\\mu L^{-1}}$. He takes lisinopril for hypertension and metformin for type $2$ diabetes mellitus. He has no known human immunodeficiency virus (HIV) infection. His weight is $96\\,\\mathrm{kg}$, height is $170\\,\\mathrm{cm}$, and serum creatinine is $2.8\\,\\mathrm{mg/dL}$. \n\nYour institution’s Pneumocystis jirovecii pneumonia (PJP) prophylaxis protocol uses oral trimethoprim-sulfamethoxazole (TMP-SMX) operationalized as follows for adults:\n- Base daily trimethoprim dose is $2\\,\\mathrm{mg}\\cdot\\mathrm{kg}^{-1}\\cdot\\mathrm{day}^{-1}$.\n- A cap is applied at a maximum of $160\\,\\mathrm{mg}$ trimethoprim per day to mitigate cytopenia risk.\n- For estimated creatinine clearance between $15$ and $30\\,\\mathrm{mL/min}$, total weekly trimethoprim exposure is reduced by a factor of $0.5$, and once-daily dosing is preserved by switching to the nearest available tablet strength (single-strength tablet containing $80\\,\\mathrm{mg}$ trimethoprim or double-strength tablet containing $160\\,\\mathrm{mg}$ trimethoprim), rounding to the nearest available strength.\n- For estimated creatinine clearance $15\\,\\mathrm{mL/min}$, TMP-SMX prophylaxis is avoided.\n\nAssume use of adjusted body weight if body mass index (BMI) is at least $30\\,\\mathrm{kg/m^2}$, ideal body weight defined for males as $50\\,\\mathrm{kg} + 2.3\\,\\mathrm{kg}$ per inch over $5$ feet, and adjusted body weight defined as $\\mathrm{IBW} + 0.4\\times(\\mathrm{Actual} - \\mathrm{IBW})$. Estimate creatinine clearance with the Cockcroft–Gault equation for males: $\\mathrm{CrCl} = \\frac{(140-\\text{age})\\times\\text{weight}}{72\\times \\text{SCr}}$, where weight is as specified above.\n\nStarting only from well-established host-defense principles, recognized PJP prophylaxis indications across diseases and drug exposures, and standard clinical pharmacology facts, determine whether PJP prophylaxis is warranted and, if so, calculate the regimen’s final total weekly trimethoprim amount (in milligrams) under the protocol, including the renal adjustment and tablet-strength rounding rule. Express the final weekly trimethoprim amount in $\\mathrm{mg}$ and round your answer to four significant figures.",
            "solution": "The problem is validated as follows.\n\n**Step 1: Extract Givens**\n-   Patient Age: $70$ years\n-   Diagnosis: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis\n-   Immunosuppressive Medications: Single infusion of rituximab, oral prednisone at $40\\,\\mathrm{mg/day}$ for $6$ consecutive weeks, oral cyclophosphamide induction.\n-   Other Medications: Lisinopril, metformin.\n-   Patient Biometrics:\n    -   Weight (Actual Body Weight, ABW): $96\\,\\mathrm{kg}$\n    -   Height: $170\\,\\mathrm{cm}$\n-   Laboratory Values:\n    -   Absolute lymphocyte count: $250\\,\\mathrm{\\mu L^{-1}}$\n    -   Serum creatinine (SCr): $2.8\\,\\mathrm{mg/dL}$\n-   Human immunodeficiency virus (HIV) status: No known infection.\n-   Body Weight Definitions for Calculation:\n    -   Ideal Body Weight (IBW) for males: $50\\,\\mathrm{kg} + 2.3\\,\\mathrm{kg}$ per inch over $5$ feet.\n    -   Adjusted Body Weight (AdjBW): $\\mathrm{IBW} + 0.4\\times(\\mathrm{Actual} - \\mathrm{IBW})$.\n    -   Condition for use: Use AdjBW if Body Mass Index (BMI) is at least $30\\,\\mathrm{kg/m^2}$.\n-   Creatinine Clearance (CrCl) Estimation:\n    -   Equation (Cockcroft–Gault for males): $\\mathrm{CrCl} = \\frac{(140-\\text{age})\\times\\text{weight}}{72\\times \\text{SCr}}$.\n    -   The 'weight' used in the equation is specified by the body weight definitions above.\n-   *Pneumocystis jirovecii* pneumonia (PJP) Prophylaxis Protocol:\n    -   Drug: Oral trimethoprim-sulfamethoxazole (TMP-SMX).\n    -   Base daily trimethoprim (TMP) dose: $2\\,\\mathrm{mg}\\cdot\\mathrm{kg}^{-1}\\cdot\\mathrm{day}^{-1}$.\n    -   Dose cap: Maximum of $160\\,\\mathrm{mg}$ TMP per day.\n    -   Renal Adjustment 1: For CrCl between $15$ and $30\\,\\mathrm{mL/min}$, reduce total weekly TMP exposure by a factor of $0.5$. Preserve once-daily dosing by rounding to the nearest available tablet strength ($80\\,\\mathrm{mg}$ or $160\\,\\mathrm{mg}$ TMP).\n    -   Renal Adjustment 2: For CrCl $15\\,\\mathrm{mL/min}$, avoid TMP-SMX.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, objective, and complete. It presents a realistic clinical scenario involving a patient with a severe autoimmune disease receiving standard, potent immunosuppressive therapy. The risk of PJP in such patients is a well-established clinical concern. The provided prophylaxis protocol, while specific to a hypothetical institution, is internally consistent and based on standard pharmacological principles, including dose adjustment for renal impairment and obesity. All necessary data and equations for solving the problem are provided. There are no contradictions, ambiguities, or violations of scientific or logical principles.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Part 1: Justification for PJP Prophylaxis**\n\nPJP prophylaxis is unequivocally warranted in this patient. The justification rests on several well-established host-defense principles and risk factors, all of which are present.\n1.  **High-Dose Glucocorticoid Therapy:** The patient is receiving prednisone at a dose of $40\\,\\mathrm{mg/day}$. The standard threshold for PJP prophylaxis is prednisone exposure equivalent to $\\ge 20\\,\\mathrm{mg/day}$ for a duration of $\\ge 1$ month. This patient's regimen of $40\\,\\mathrm{mg/day}$ for $6$ weeks ($1.5$ months) is substantially above this threshold. Glucocorticoids impair cell-mediated immunity, which is the primary defense against *Pneumocystis jirovecii*.\n2.  **Combination of Potent Immunosuppressants:** The patient is on a triple-drug induction regimen. The combination of prednisone (a corticosteroid), cyclophosphamide (an alkylating agent cytotoxic to lymphocytes), and rituximab (a B-cell depleting anti-CD20 monoclonal antibody) results in profound, multi-faceted immunosuppression. The American Thoracic Society and other major guidelines strongly recommend prophylaxis for patients receiving cyclophosphamide, and the risk is compounded by the concurrent agents.\n3.  **Severe Lymphopenia:** A critical indicator of impaired cell-mediated immunity is a low absolute lymphocyte count (ALC). This patient's ALC is $250\\,\\mathrm{\\mu L^{-1}}$ (or $0.25 \\times 10^9\\,\\mathrm{L^{-1}}$). This value is severely low and a strong independent predictor of PJP risk.\nGiven these multiple, compelling risk factors, initiating PJP prophylaxis is mandatory standard of care.\n\n**Part 2: Calculation of the Prophylactic Regimen**\n\nThe calculation proceeds sequentially according to the institutional protocol.\n\n**Step 2a: Determine the Appropriate Body Weight for Calculation**\nFirst, we calculate the patient's Body Mass Index (BMI) to determine which weight measure to use.\nHeight: $170\\,\\mathrm{cm} = 1.70\\,\\mathrm{m}$.\nWeight (ABW): $96\\,\\mathrm{kg}$.\n$$ \\mathrm{BMI} = \\frac{\\text{weight in kg}}{(\\text{height in m})^2} = \\frac{96\\,\\mathrm{kg}}{(1.70\\,\\mathrm{m})^2} = \\frac{96}{2.89}\\,\\mathrm{kg/m^2} \\approx 33.22\\,\\mathrm{kg/m^2} $$\nSince the BMI ($33.22\\,\\mathrm{kg/m^2}$) is $\\ge 30\\,\\mathrm{kg/m^2}$, the protocol dictates the use of Adjusted Body Weight (AdjBW) for calculations.\n\n**Step 2b: Calculate Ideal Body Weight (IBW) and Adjusted Body Weight (AdjBW)**\nFirst, convert height to inches. $1\\,\\mathrm{inch} = 2.54\\,\\mathrm{cm}$.\n$$ \\text{Height in inches} = 170\\,\\mathrm{cm} \\times \\frac{1\\,\\mathrm{inch}}{2.54\\,\\mathrm{cm}} \\approx 66.929\\,\\mathrm{inches} $$\nThe number of inches over $5$ feet ($60$ inches) is $66.929 - 60 = 6.929\\,\\mathrm{inches}$.\nNow, calculate IBW for a male:\n$$ \\mathrm{IBW} = 50\\,\\mathrm{kg} + 2.3\\,\\mathrm{kg/inch} \\times (6.929\\,\\mathrm{inches}) \\approx 50\\,\\mathrm{kg} + 15.937\\,\\mathrm{kg} \\approx 65.937\\,\\mathrm{kg} $$\nNext, calculate AdjBW:\n$$ \\mathrm{AdjBW} = \\mathrm{IBW} + 0.4 \\times (\\mathrm{ABW} - \\mathrm{IBW}) $$\n$$ \\mathrm{AdjBW} = 65.937\\,\\mathrm{kg} + 0.4 \\times (96\\,\\mathrm{kg} - 65.937\\,\\mathrm{kg}) = 65.937\\,\\mathrm{kg} + 0.4 \\times (30.063\\,\\mathrm{kg}) $$\n$$ \\mathrm{AdjBW} = 65.937\\,\\mathrm{kg} + 12.025\\,\\mathrm{kg} = 77.962\\,\\mathrm{kg} $$\nThis is the weight to be used for CrCl estimation and dosing.\n\n**Step 2c: Estimate Creatinine Clearance (CrCl)**\nUsing the Cockcroft-Gault equation with AdjBW for weight:\n$$ \\mathrm{CrCl} = \\frac{(140-\\text{age})\\times\\text{weight}}{72\\times \\text{SCr}} = \\frac{(140 - 70) \\times 77.962\\,\\mathrm{kg}}{72 \\times 2.8\\,\\mathrm{mg/dL}} $$\n$$ \\mathrm{CrCl} = \\frac{70 \\times 77.962}{201.6} = \\frac{5457.34}{201.6} \\approx 27.07\\,\\mathrm{mL/min} $$\n\n**Step 2d: Apply the Protocol's Renal Adjustment Rule**\nThe calculated CrCl of $27.07\\,\\mathrm{mL/min}$ falls within the range of $15$ to $30\\,\\mathrm{mL/min}$. The protocol for this range requires reducing the total weekly TMP exposure by a factor of $0.5$ and then rounding the daily dose to the nearest available tablet strength.\n\n**Step 2e: Calculate Target Daily and Final Weekly Dose**\nFirst, calculate the unadjusted base daily TMP dose using AdjBW:\n$$ \\text{Base Daily Dose} = 2\\,\\mathrm{mg}\\cdot\\mathrm{kg}^{-1}\\cdot\\mathrm{day}^{-1} \\times 77.962\\,\\mathrm{kg} \\approx 155.92\\,\\mathrm{mg/day} $$\nThis dose is below the daily cap of $160\\,\\mathrm{mg}$, so the cap is not applied.\n\nNext, apply the renal adjustment factor of $0.5$. The \"total weekly trimethoprim exposure is reduced by a factor of $0.5$\". This is equivalent to halving the target daily dose.\n$$ \\text{Target Renally-Adjusted Daily Dose} = 155.92\\,\\mathrm{mg/day} \\times 0.5 \\approx 77.96\\,\\mathrm{mg/day} $$\n\nThe protocol requires rounding this target daily dose to the nearest available tablet strength ($80\\,\\mathrm{mg}$ or $160\\,\\mathrm{mg}$).\nThe target dose is $77.96\\,\\mathrm{mg}$.\nThe distance to $80\\,\\mathrm{mg}$ is $|80 - 77.96| = 2.04$.\nThe distance to $160\\,\\mathrm{mg}$ is $|160 - 77.96| = 82.04$.\nThe nearest available strength is the $80\\,\\mathrm{mg}$ single-strength (SS) tablet. Thus, the prescribed daily dose is $80\\,\\mathrm{mg}$ of trimethoprim.\n\nFinally, calculate the total weekly trimethoprim amount based on this prescribed daily dose.\n$$ \\text{Final Total Weekly Amount} = 80\\,\\mathrm{mg/day} \\times 7\\,\\mathrm{days/week} = 560\\,\\mathrm{mg} $$\nThe problem asks for the answer to be rounded to four significant figures. To express $560$ with four significant figures, we write it as $560.0$.",
            "answer": "$$\\boxed{560.0}$$"
        },
        {
            "introduction": "The diagnosis of invasive fungal infections is often fraught with uncertainty, relying on specialized biomarker tests that are powerful but imperfect. Bayes' theorem provides a rigorous mathematical framework for clinicians to quantify and update their diagnostic suspicion in light of new information. This problem offers a hands-on application of Bayesian reasoning, guiding you through the calculation of a post-test probability of disease and demonstrating how this quantitative result can be integrated with a clinical decision threshold to determine whether to initiate therapy. ",
            "id": "4854814",
            "problem": "A patient with acute myeloid leukemia undergoing induction chemotherapy has profound neutropenia and new pulmonary nodules. Bronchoalveolar Lavage (BAL) galactomannan is positive, defined by a galactomannan index above the laboratory cutoff. In this setting, the pretest probability of invasive mold disease (IMD) before the BAL result is estimated as $p_{0} = 0.30$. The BAL galactomannan assay has sensitivity $s = 0.85$ and specificity $c = 0.90$ for IMD.\n\nUsing only the fundamental definitions of sensitivity, specificity, conditional probability, and the law of total probability, derive and compute the posterior probability of IMD given a positive BAL galactomannan. Then, using an expected utility framework, determine whether to initiate mold-active antifungal therapy immediately by comparing the posterior probability to a treatment threshold derived from the following quantities: if IMD is truly present and therapy is initiated early, the estimated absolute reduction in $30$-day mortality is $B = 0.18$ (mortality-equivalent benefit); if IMD is absent but therapy is initiated, the estimated mortality-equivalent harm from toxicity and complications is $H = 0.02$. Treat only if the posterior probability exceeds the threshold implied by these values. Express the posterior probability as a decimal rounded to four significant figures. Provide the numerical posterior probability as your final answer.",
            "solution": "The problem is valid. It is a well-posed application of Bayesian inference and decision theory to a clinically relevant scenario in internal medicine. All necessary data are provided, the terminology is precise, and the framework is scientifically sound.\n\nThe first objective is to compute the posterior probability of invasive mold disease (IMD) given a positive Bronchoalveolar Lavage (BAL) galactomannan test. Let $D$ be the event that the patient has IMD, and let $T^+$ be the event that the BAL galactomannan test is positive.\n\nThe givens from the problem statement are:\n- The pretest probability (prevalence) of IMD: $P(D) = p_0 = 0.30$.\n- The sensitivity of the test, which is the probability of a positive test given the presence of disease: $P(T^+|D) = s = 0.85$.\n- The specificity of the test, which is the probability of a negative test given the absence of disease: $P(T^-|D^c) = c = 0.90$, where $D^c$ is the complement of $D$ (i.e., the patient does not have IMD).\n\nFrom these givens, we can derive two additional probabilities necessary for the calculation.\nFirst, the probability of not having IMD is the complement of the pretest probability:\n$$P(D^c) = 1 - P(D) = 1 - 0.30 = 0.70$$\nSecond, the probability of a positive test in a patient without IMD (the false positive rate) is the complement of the specificity:\n$$P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - c = 1 - 0.90 = 0.10$$\n\nThe posterior probability, $P(D|T^+)$, can be calculated using Bayes' theorem, which is derived from the definition of conditional probability:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of a positive test. It can be expanded using the law of total probability by conditioning on the presence or absence of disease:\n$$P(T^+) = P(T^+|D)P(D) + P(T^+|D^c)P(D^c)$$\nSubstituting this expansion into Bayes' theorem gives the full formula for the posterior probability:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+|D)P(D) + P(T^+|D^c)P(D^c)}$$\nNow, we substitute the numerical values into this formula:\n$$P(D|T^+) = \\frac{(0.85)(0.30)}{(0.85)(0.30) + (0.10)(0.70)}$$\n$$P(D|T^+) = \\frac{0.255}{0.255 + 0.070} = \\frac{0.255}{0.325}$$\nCalculating the value of this fraction gives:\n$$P(D|T^+) \\approx 0.78461538...$$\nAs requested, rounding to four significant figures yields a posterior probability of $0.7846$.\n\nThe second part of the problem requires a decision on whether to initiate therapy using an expected utility framework. We must compare the posterior probability to a treatment threshold. The threshold is the probability of disease at which the expected utility of treating equals the expected utility of withholding treatment. Let $p$ be the probability of disease, which in our case is the posterior probability $P(D|T^+)$.\n\nThe given utility-related quantities are:\n- The mortality-equivalent benefit of treating a patient who truly has IMD: $B = 0.18$.\n- The mortality-equivalent harm of treating a patient who does not have IMD: $H = 0.02$.\n\nWe can define the net expected benefit of initiating therapy. If the patient has the disease (with probability $p$), we gain a benefit $B$. If the patient does not have the disease (with probability $1-p$), we incur a harm $H$. The expected net benefit of treatment is therefore:\n$$E[\\text{Benefit}_{\\text{Treat}}] = p \\cdot B - (1-p) \\cdot H$$\nThe rational decision is to treat if the expected net benefit is greater than zero (i.e., greater than the benefit of the alternative, which is withholding treatment, defined here as the baseline of $0$).\n$$p \\cdot B - (1-p) \\cdot H  0$$\nWe solve this inequality for $p$ to find the treatment threshold, denoted $p_T$:\n$$pB  (1-p)H$$\n$$pB  H - pH$$\n$$pB + pH  H$$\n$$p(B+H)  H$$\n$$p  \\frac{H}{B+H}$$\nThus, the treatment threshold is $p_T = \\frac{H}{B+H}$. Substituting the given values:\n$$p_T = \\frac{0.02}{0.18 + 0.02} = \\frac{0.02}{0.20} = 0.10$$\nThe decision rule is to initiate therapy if the posterior probability of IMD exceeds this threshold. We must compare our calculated posterior probability to this threshold:\n$$P(D|T^+) \\approx 0.7846$$\n$$p_T = 0.10$$\nSince $0.7846  0.10$, the posterior probability of IMD is substantially higher than the treatment threshold. Therefore, based on this expected utility framework, the decision should be to initiate mold-active antifungal therapy immediately.\n\nThe problem asks for the numerical posterior probability as the final answer.\nPosterior Probability $= 0.7846$.",
            "answer": "$$\n\\boxed{0.7846}\n$$"
        }
    ]
}